BACKGROUND:Recombinant interleukin-2 (rIL-2) induces cellular cytotoxicity against leukemia blasts. Patients with acute myeloid leukemia (AML) in first complete remission (CR) may harbor minimal residual disease that is susceptible to rIL-2-activated effector cells. METHODS: In the Cancer and Leukemia Group B (CALGB) 19808 study, patients with AML in first CR were randomly assigned after all planned chemotherapy to receive a 90-day course of subcutaneously administered rIL-2 or no further therapy. The primary objective was to compare disease-free survival (DFS) between the 2 treatment arms. A total of 534 patients achieved a CR, 214 of whom were randomized. Six courses of low-dose daily rIL-2 were given for the expansion of cytotoxic effector cells, each followed by 3-day high-dose boluses given to trigger cytotoxicity against minimal residual disease. RESULTS: On the protocol-specified intention-to-treat analysis, the hazards ratio for DFS was 0.75 (95% confidence interval, 0.52-1.09; P = .13); the 5-year DFS rate was 42% in the observation arm and 53% in the rIL-2 treatment arm. The hazards ratio for overall survival (OS) was 0.88 (95% confidence interval, 0.54-1.23; P = .34); the 5-year OS rate was 58% for the observation arm and 63% for the rIL-2 treatment arm. Twenty-five of the 107 patients randomized to treatment withrIL-2 either refused or were unable to initiate therapy and 30 patients did not complete their assigned therapy. However, significant toxicities were not commonly observed. The trial design did not anticipate the difficulties patients would encounter with protocol compliance. CONCLUSIONS: The efficacy of immunotherapy with rIL-2 administered after intensive postremission treatment was not assessed as planned because of unexpected refusals by patients and/or their physicians to comply with protocol-directed therapy. Neither DFS nor OS was found to be significantly improved.
RCT Entities:
BACKGROUND: Recombinant interleukin-2 (rIL-2) induces cellular cytotoxicity against leukemia blasts. Patients with acute myeloid leukemia (AML) in first complete remission (CR) may harbor minimal residual disease that is susceptible to rIL-2-activated effector cells. METHODS: In the Cancer and Leukemia Group B (CALGB) 19808 study, patients with AML in first CR were randomly assigned after all planned chemotherapy to receive a 90-day course of subcutaneously administered rIL-2 or no further therapy. The primary objective was to compare disease-free survival (DFS) between the 2 treatment arms. A total of 534 patients achieved a CR, 214 of whom were randomized. Six courses of low-dose daily rIL-2 were given for the expansion of cytotoxic effector cells, each followed by 3-day high-dose boluses given to trigger cytotoxicity against minimal residual disease. RESULTS: On the protocol-specified intention-to-treat analysis, the hazards ratio for DFS was 0.75 (95% confidence interval, 0.52-1.09; P = .13); the 5-year DFS rate was 42% in the observation arm and 53% in the rIL-2 treatment arm. The hazards ratio for overall survival (OS) was 0.88 (95% confidence interval, 0.54-1.23; P = .34); the 5-year OS rate was 58% for the observation arm and 63% for the rIL-2 treatment arm. Twenty-five of the 107 patients randomized to treatment with rIL-2 either refused or were unable to initiate therapy and 30 patients did not complete their assigned therapy. However, significant toxicities were not commonly observed. The trial design did not anticipate the difficulties patients would encounter with protocol compliance. CONCLUSIONS: The efficacy of immunotherapy with rIL-2 administered after intensive postremission treatment was not assessed as planned because of unexpected refusals by patients and/or their physicians to comply with protocol-directed therapy. Neither DFS nor OS was found to be significantly improved.
Authors: C A Linker; C A Ries; L E Damon; P Sayre; W Navarro; H S Rugo; A Rubin; D Case; P Crilley; D Topolsky; I Brodsky; K Zamkoff; J L Wolfe Journal: Biol Blood Marrow Transplant Date: 2000 Impact factor: 5.742
Authors: D Blaise; M Attal; J Reiffers; M Michallet; C Bellanger; J L Pico; A M Stoppa; C Payen; G Marit; R Bouabdallah; J J Sotto; J F Rossi; M Brandely; T Hercend; D Maraninchi Journal: Eur Cytokine Netw Date: 2000-03 Impact factor: 2.737
Authors: Sherif S Farag; Kellie J Archer; Krzysztof Mrózek; James W Vardiman; Andrew J Carroll; Mark J Pettenati; Joseph O Moore; Jonathan E Kolitz; Robert J Mayer; Richard M Stone; Richard A Larson; Clara D Bloomfield Journal: Int J Oncol Date: 2002-11 Impact factor: 5.650
Authors: B D Cheson; P A Cassileth; D R Head; C A Schiffer; J M Bennett; C D Bloomfield; R Brunning; R P Gale; M R Grever; M J Keating Journal: J Clin Oncol Date: 1990-05 Impact factor: 44.544
Authors: Jonathan E Kolitz; Stephen L George; Richard K Dodge; David D Hurd; Bayard L Powell; Steven L Allen; Enrique Velez-Garcia; Joseph O Moore; Thomas C Shea; Eva Hoke; Michael A Caligiuri; James W Vardiman; Clara D Bloomfield; Richard A Larson Journal: J Clin Oncol Date: 2004-11-01 Impact factor: 44.544
Authors: D Maraninchi; D Blaise; P Viens; M Brandely; D Olive; M Lopez; D Sainty; G Marit; A M Stoppa; J Reiffers Journal: Blood Date: 1991-11-01 Impact factor: 22.113
Authors: Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio Journal: Blood Date: 2016-06-27 Impact factor: 22.113
Authors: Selina M Luger; Victoria X Wang; Jacob M Rowe; Mark R Litzow; Elisabeth Paietta; Rhett P Ketterling; Hillard Lazarus; Witold B Rybka; Michael D Craig; Judith Karp; Brenda W Cooper; Adel Z Makary; Lynne S Kaminer; Frederick R Appelbaum; Richard A Larson; Martin S Tallman Journal: Leuk Res Date: 2021-10-28 Impact factor: 3.156
Authors: Jorge J Castillo; Flora Mulkey; Susan Geyer; Jonathan E Kolitz; William Blum; Bayard L Powell; Stephen L George; Richard A Larson; Richard M Stone Journal: Am J Hematol Date: 2015-11-26 Impact factor: 10.047
Authors: Michael Boyiadzis; Michael R Bishop; Rafat Abonour; Kenneth C Anderson; Stephen M Ansell; David Avigan; Lisa Barbarotta; Austin John Barrett; Koen Van Besien; P Leif Bergsagel; Ivan Borrello; Joshua Brody; Jill Brufsky; Mitchell Cairo; Ajai Chari; Adam Cohen; Jorge Cortes; Stephen J Forman; Jonathan W Friedberg; Ephraim J Fuchs; Steven D Gore; Sundar Jagannath; Brad S Kahl; Justin Kline; James N Kochenderfer; Larry W Kwak; Ronald Levy; Marcos de Lima; Mark R Litzow; Anuj Mahindra; Jeffrey Miller; Nikhil C Munshi; Robert Z Orlowski; John M Pagel; David L Porter; Stephen J Russell; Karl Schwartz; Margaret A Shipp; David Siegel; Richard M Stone; Martin S Tallman; John M Timmerman; Frits Van Rhee; Edmund K Waller; Ann Welsh; Michael Werner; Peter H Wiernik; Madhav V Dhodapkar Journal: J Immunother Cancer Date: 2016-12-20 Impact factor: 13.751
Authors: Reza Ghasemi; Eric Lazear; Xiaoli Wang; Saeed Arefanian; Alexander Zheleznyak; Beatriz M Carreno; Ryuji Higashikubo; Andrew E Gelman; Daniel Kreisel; Daved H Fremont; Alexander Sasha Krupnick Journal: Nat Commun Date: 2016-09-21 Impact factor: 14.919
Authors: Anna Martner; Anna Rydström; Rebecca E Riise; Johan Aurelius; Harald Anderson; Mats Brune; Robin Foà; Kristoffer Hellstrand; Fredrik B Thorén Journal: Oncoimmunology Date: 2015-05-05 Impact factor: 8.110